The purpose of the Animal Model and Therapeutics Evaluation Core (AMTEC) is to enhance the peer reviewed funded research activities of KCI members whose research needs involve the use of animal models. Our goal is to provide expert scientific consultation, technical expertise and access to a wide breadth of relevant tumor models and associated animal-related services. AMTEC is grouped in the Basic Research Core Cluster which, in addition to AMTEC, includes the Proteomics Core and the Microscopy, Imaging and Cytometry Resources Core (MICR). Established in 2012, the services provided by the AMTEC Core have already contributed to 14 peer-reviewed publications. AMTEC maintains and distributes cancer models and authenticated cell lines originally developed at KCI; conducts in vivo testing of novel therapeutics; and assists investigators in many aspects of small animal research. AMTEC also makes it easier for an investigator to utilize other appropriate cores for follow-up analysis, i.e. provides assistance with administration of anesthesia, study drugs, contrast agents and radioactive tracers, to post?procedure recovery and health care monitoring for small animal imaging; and generates in vivo derived tissues and samples for analysis in the Proteomics, Biobanking and Correlative Sciences (BCS), Pharmacology and Genomics Cores. Core operations are currently centered within the conveniently located Prentis Cancer Research Building animal facility, allowing AMTEC personnel to be within two-three blocks of the primary laboratory locations of most Cancer Center members and all on-site animal studies. Our resources include barrier animal holding rooms for immuno-compromised or transgenic mice, and biosafety Level-2 areas for carcinogen and chemotherapeutic experiments, manipulations and necropsy. Each AMTEC staff member has extensive small animal expertise (with a minimum 25 years of training and experience) and possesses a high level of proficiency in small animal techniques and procedures. Core staff members have not only successfully completed all Institutional Animal Care and Use Committee (IACUC) mandated small animal and surgery training courses; they also possess on-site certifications to handle radioactive materials, blood-borne pathogens, hazardous agents and operate x-ray generating equipment. Certifications are reviewed and updated annually and supplemented with ongoing ad-hoc training to expand expertise in various techniques and procedures so that AMTEC can knowledgeably and competently assist Cancer Center members with design and execution of their in vivo studies. A major strength of AMTEC is the extensive expertise in testing novel therapeutic agents in syngeneic and xenogeneic tumor systems. All animal work is carried out solely under protocols approved by the IACUC and upon completion of animal care training. AMTEC can also augment and assist investigators in meeting these requirements and in developing competent proficiency.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA022453-37
Application #
9605738
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2018-12-01
Budget End
2019-11-30
Support Year
37
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Wayne State University
Department
Type
DUNS #
001962224
City
Detroit
State
MI
Country
United States
Zip Code
48202
Li, Feng; Wang, Yongli; Li, Dapeng et al. (2018) Perspectives on the recent developments with green tea polyphenols in drug discovery. Expert Opin Drug Discov 13:643-660
Ramseyer, Vanesa D; Kimler, Victoria A; Granneman, James G (2018) Vacuolar protein sorting 13C is a novel lipid droplet protein that inhibits lipolysis in brown adipocytes. Mol Metab 7:57-70
Healy, Mark A; Morris, Arden M; Abrahamse, Paul et al. (2018) The accuracy of chemotherapy ascertainment among colorectal cancer patients in the surveillance, epidemiology, and end results registry program. BMC Cancer 18:481
Lacher, Sarah E; Alazizi, Adnan; Wang, Xuting et al. (2018) A hypermorphic antioxidant response element is associated with increased MS4A6A expression and Alzheimer's disease. Redox Biol 14:686-693
Alsaab, Hashem O; Sau, Samaresh; Alzhrani, Rami M et al. (2018) Tumor hypoxia directed multimodal nanotherapy for overcoming drug resistance in renal cell carcinoma and reprogramming macrophages. Biomaterials 183:280-294
Chammaa, May; Malysa, Agnes; Redondo, Carlos et al. (2018) RUMI is a novel negative prognostic marker and therapeutic target in non-small-cell lung cancer. J Cell Physiol 233:9548-9562
Vaishampayan, Ulka N; Podgorski, Izabela; Heilbrun, Lance K et al. (2018) Biomarkers and Bone Imaging Dynamics Associated with Clinical Outcomes of Oral Cabozantinib Therapy in Metastatic Castrate-Resistant Prostate Cancer. Clin Cancer Res :
Mills, Anne M; Peres, Lauren C; Meiss, Alice et al. (2018) Targetable Immune Regulatory Molecule Expression in High-Grade Serous Ovarian Carcinomas in African American Women: A Study of PD-L1 and IDO in 112 Cases From the African American Cancer Epidemiology Study (AACES). Int J Gynecol Pathol :
Campbell, Douglas H; Lund, Maria E; Nocon, Aline L et al. (2018) Detection of glypican-1 (GPC-1) expression in urine cell sediments in prostate cancer. PLoS One 13:e0196017
Sexton, Rachel E; Hachem, Ali H; Assi, Ali A et al. (2018) Metabotropic glutamate receptor-1 regulates inflammation in triple negative breast cancer. Sci Rep 8:16008

Showing the most recent 10 out of 826 publications